After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

When it comes to molding processes in plastics manufacturing, achieving a consistent flow can sometimes feel like trying to steer a ship through rocky waters. The secret to success lies in mastering ...

As the premier consumer L1 network, Flow has proven that incubating killer apps is as vital as fostering a robust, open infrastructure. Flow launched its network with groundbreaking partnerships, ...

NEW YORK, Dec 4 (Reuters Breakingviews) - Warren Buffett often said that the stock market is a voting machine in the short run, but a weighing machine over longer horizons. The outgoing Berkshire ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS). RRMS ...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...

Inside Claude-Flow: Using Multi-Agent AI to Modernize Legacy Applications Faster Your email has been sent Multi-agent AI orchestration frameworks like Claude-Flow help teams modernize legacy ...

Management expects to request an end of Phase II meeting with the FDA in Q4 2025 to gain alignment on the Phase III program for chronic cough in IPF and to discuss NDA-enabling work. The company is ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis - The first (FENhance ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ...

Oct 29 (Reuters) - Myanmar's military government will hold the second phase of its multi-stage election on January 11, state media said on Wednesday, a vote dismissed as a sham by Western countries, ...